1. Analyst View 2. Research Methodology 3. Introduction 4. Global T-Cell Immunotherapy Market for Cancer 5. Global CAR T-Cell Immunotherapy Market for Cancer 6. Commercialized CAR T-Cell Immunotherapies for Cancer 6.1 Kymriah 6.2 Yescarta 7. Major Therapeutic Areas for T-Cell Immunotherapies 7.1 Hematological Malignancies 7.1.1 Leukemia 7.1.2 Lymphoma 7.1.3 Multiple Myeloma 7.2 Solid Tumors 7.2.1 Melanoma 7.2.2 Bladder Cancer 7.2.3 Kidney Cancer 7.2.4 Ovarian Cancer 7.2.5 Breast Cancer 7.2.6 Lung Cancer 8. T-Cell Immunotherapy Pipeline Analysis 8.1 By Industry 8.1.1 By Vector 8.1.2 By Clinical Trial Phase 8.1.3 By Indication 8.1.4 By Technology 8.1.5 By Key Players 8.1.6 By Geography 8.2 By Research Collaborations 9. Market Opportunities 10. Key Player Analysis 10.1 Adaptimmune Therapeutics plc 10.2 Juno Therapeutics, Inc. 10.3 Gilead Sciences, Inc. 10.4 Novartis International AG 10.5 Tessa Therapeutics Pte Ltd. 10.6 Gradalis, Inc. 10.7 Immunovative Therapies, Ltd. 10.8 Iovance Biotherapeutics, Inc. (Formerly Lion Biotechnologies, Inc.) 10.9 Atara Biotherapeutics, Inc. 10.10 Celgene Corporation 10.11 Cellular Biomedicine Group 10.12 GlaxoSmithKline plc. 10.13 Immunocore Ltd. 10.14 Inovio Pharmaceuticals, Inc. 10.15 Cell Medica

List of Tables: Table 4-1: Global - Major Venture Capitalist Investment in T-Cell Immunotherapy (Million US$), 2014-2017 Table 4-2: Global - Major IPO Raised in T-Cell Immunotherapy (Million US$), 2014-2017 Table 4-3: Global - Acquisitions and Collaborations in T-Cell Immunotherapy (Million US$), 2014-2017 Table 7-1: Global - Cancer Prevalence (Million), 2015 & 2025 Table 7-2: Global - Leukemia Prevalence (‘000), 2015 & 2025 Table 7-3: North America - Leukemia Prevalence (‘000), 2015 & 2025 Table 7-4: Europe - Leukemia Prevalence (‘000), 2015 & 2025 Table 7-5: Asia-Pacific - Leukemia Prevalence (‘000), 2015 & 2025 Table 7-6: Rest of the World - Leukemia Prevalence (‘000), 2015 & 2025 Table 7-7: Global - Lymphoma Prevalence (‘000), 2015 & 2025 Table 7-8: North America - Lymphoma Prevalence (‘000), 2015 & 2025 Table 7-9: Europe - Lymphoma Prevalence (‘000), 2015 & 2025 Table 7-10: Asia-Pacific - Lymphoma Prevalence (‘000), 2015 & 2025 Table 7-11: Rest of the World - Lymphoma Prevalence (‘000), 2015 & 2025 Table 7-12: Global - Multiple Myeloma Prevalence (‘000), 2015 & 2025 Table 7-13: North America - Multiple Myeloma Prevalence (‘000), 2015 & 2025 Table 7-14: Europe - Multiple Myeloma Prevalence (‘000), 2015 & 2025 Table 7-15: Asia-Pacific - Multiple Myeloma Prevalence (‘000), 2015 & 2025 Table 7-16: Rest of the World - Multiple Myeloma Prevalence (‘000), 2015 & 2025 Table 7-17: Global - Melanoma Prevalence (‘000), 2015 & 2025 Table 7-18: North America - Melanoma Prevalence (‘000), 2015 & 2025 Table 7-19: Europe - Melanoma Prevalence (‘000), 2015 & 2025 Table 7-20: Asia-Pacific - Melanoma Prevalence (‘000), 2015 & 2025 Table 7-21: Rest of the World - Melanoma Prevalence (‘000), 2015 & 2025 Table 7-22: Global - Bladder Cancer Prevalence (‘000), 2015 & 2025 Table 7-23: North America - Bladder Cancer Prevalence (‘000), 2015 & 2025 Table 7-24: Europe - Bladder Cancer Prevalence (‘000), 2015 & 2025 Table 7-25: Asia-Pacific - Bladder Cancer Prevalence (‘000), 2015 & 2025 Table 7-26: Rest of the World - Bladder Cancer Prevalence (‘000), 2015 & 2025 Table 7-27: Global - Kidney Cancer Prevalence (‘000), 2015 & 2025 Table 7-28: North America - Kidney Cancer Prevalence (‘000), 2015 & 2025 Table 7-29: Europe - Kidney Cancer Prevalence (‘000), 2015 & 2025 Table 7-30: Asia-Pacific - Kidney Cancer Prevalence (‘000), 2015 & 2025 Table 7-31: Rest of the World - Kidney Cancer Prevalence (‘000), 2015 & 2025 Table 7-32: Global - Ovarian Cancer Prevalence (‘000), 2015 & 2025 Table 7-33: North America - Ovarian Cancer Prevalence (‘000), 2015 & 2025 Table 7-34: Europe - Ovarian Cancer Prevalence (‘000), 2015 & 2025 Table 7-35: Asia-Pacific - Ovarian Cancer Prevalence (‘000), 2015 & 2025 Table 7-36: Rest of the World - Ovarian Cancer Prevalence (‘000), 2015 & 2025 Table 7-37: Global - Breast Cancer Prevalence (‘000), 2015 & 2025 Table 7-38: North America - Breast Cancer Prevalence (‘000), 2015 & 2025 Table 7-39: Europe - Breast Cancer Prevalence (‘000), 2015 & 2025 Table 7-40: Asia-Pacific - Breast Cancer Prevalence (‘000), 2015 & 2025 Table 7-41: Rest of the World - Breast Cancer Prevalence (‘000), 2015 & 2025 Table 7-42: Global - Lung Cancer Prevalence (‘000), 2015 & 2025 Table 7-43: North America - Lung Cancer Prevalence (‘000), 2015 & 2025 Table 7-44: Europe - Lung Cancer Prevalence (‘000), 2015 & 2025 Table 7-45: Asia-Pacific - Lung Cancer Prevalence (‘000), 2015 & 2025 Table 7-46: Rest of the World - Lung Cancer Prevalence (‘000), 2015 & 2025 Table 8-1: Global T-Cell Immunotherapy Pipeline by Industry Table 8-2: Global T-Cell Immunotherapy Pipeline by Research Collaborations Table 10-1: Adaptimmune Therapeutics plc - Revenue (Million US$), 2015 & 2016 Table 10-2: Adaptimmune Therapeutics plc - T-Cell Immunotherapy Pipeline Table 10-3: Juno Therapeutics, Inc. - Revenue (Million US$), 2015 & 2016 Table 10-4: Juno Therapeutics, Inc. - T-Cell Immunotherapy Pipeline Table 10-5: Gilead Sciences, Inc. - Total Revenue (Million US$), 2014, 2015 & 2016 Table 10-6: Gilead Sciences, Inc. - T-Cell Immunotherapy Product Portfolio Table 10-7: Gilead Sciences, Inc. - T-Cell Immunotherapy Pipeline Table 10-8: Novartis - Net Sales (Million US$), 2014, 2015 & 2016 Table 10-9: Novartis - T-Cell Immunotherapy Product Portfolio Table 10-10: Novartis - T-Cell Immunotherapy Pipeline Table 10-11: Tessa Therapeutics Pte Ltd. - T-Cell Immunotherapy Pipeline Table 10-12: Gradalis, Inc. - T-Cell Immunotherapy Pipeline Table 10-13: Immunovative Therapies, Ltd. - T-Cell Immunotherapy Pipeline Table 10-14: Iovance Biotherapeutics, Inc. - T-Cell Immunotherapy Pipeline Table 10-15: Atara Biotherapeutics, Inc. - T-Cell Immunotherapy Pipeline Table 10-16: Celgene Corporation - Total Revenue (Million US$), 2014, 2015 & 2016 Table 10-17: Celgene Corporation - T-Cell Immunotherapy Pipeline Table 10-18: Cellular Biomedicine Group - Net Sales & Revenue (Million US$), 2014, 2015 & 2016 Table 10-19: Cellular Biomedicine Group - T-Cell Immunotherapy Pipeline Table 10-20: GlaxoSmithKline plc. - Group Turnover (Million US$), 2014, 2015 & 2016 Table 10-21: GlaxoSmithKline plc. - T-Cell Immunotherapy Pipeline Table 10-22: Immunocore Ltd. - T-Cell Immunotherapy Pipeline Table 10-23: Inovio Pharmaceuticals, Inc. - Total Revenue (Million US$), 2014, 2015 & 2016 Table 10-24: Inovio Pharmaceuticals, Inc. - T-Cell Immunotherapy Pipeline Table 10-25: Cell Medica - T-Cell Immunotherapy Pipeline List of Figures: Figure 4-1: Global - T-Cell Immunotherapy Market for Cancer (Million US$), 2018 & 2022 Figure 5-1: Global - CAR T-Cell Immunotherapy Market for Cancer (Million US$), 2018 & 2022 Figure 6-1: Kymriah - Estimated Sales Forecast (Million US$), 2018 & 2022 Figure 6-2: Yescarta - Estimated Sales Forecast (Million US$), 2018 & 2022 Figure 7-1: Global - Breakup of Cancer Prevalence by Region (%), 2015 Figure 7-2: Global - Breakup of Cancer Prevalence by Region (%), 2025 Figure 8-1: Global - T-Cell Immunotherapy Pipeline Analysis by Vectors (%), 2017 Figure 8-2: Global - T-Cell Immunotherapy Pipeline Analysis by Phase (%), 2017 Figure 8-3: Global - T-Cell Immunotherapy Pipeline Analysis by Therapeutic Indication (%), 2017 Figure 8-4: Global - T-Cell Immunotherapy Pipeline Analysis by Technology (%), 2017 Figure 8-5: Global - T-Cell Immunotherapy Pipeline Analysis by Key Players (%), 2017 Figure 8-6: Global - T-Cell Immunotherapy Pipeline Analysis by Geography (%), 2017 Figure 9-1: US - CAR T-Cell Immunotherapy Potential Market for Cancer (Billion US$), 2018 & 2022 Figure 9-2: Europe - CAR T-Cell Immunotherapy Potential Market for Cancer (Billion US$), 2018 & 2022